Head and Neck Cancer Clinical Trial
Official title:
Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine
Verified date | December 2016 |
Source | University of Miami |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor
cells.
PURPOSE: This phase II trial is studying how well giving oxaliplatin together with
capecitabine works in treating patients with relapsed or metastatic head and neck cancer.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 2008 |
Est. primary completion date | April 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed head and neck cancer - Relapsed or metastatic disease - Measurable disease - No CNS metastases (unless CNS metastases have been stable for > 3 months) - No clinically significant pericardial effusion PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy > 3 months - Absolute granulocyte count > 1,500/mm³ - Platelet count > 100,000/mm³ - Bilirubin < 2.0 times upper limit of normal (ULN) - AST or ALT < 2.5 times ULN - Alkaline phosphatase < 2.5 times ULN (5 times ULN if liver metastases are present or 10 times ULN if bone disease is present) - Creatinine clearance = 30 mL/min - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 30 days after completion of study treatment - No clinically serious, uncontrolled cardiovascular disease - No New York Heart Association class III-IV heart disease - No myocardial infarction within the past 6 months - No congestive heart failure - No unstable angina - No arrhythmia - No concurrent serious, uncontrolled infections - No other cancer requiring treatment within the past 5 years, except cured nonmelanoma skin cancer or treated in situ cervical cancer - No loss of physical integrity of the upper gastrointestinal tract or malabsorption syndrome - No history of persistent neurosensory disorder including, but not limited to, peripheral neuropathy - No history of uncontrolled seizures or CNS disorders - No history of psychiatric disability or other serious uncontrolled medical condition that would preclude study compliance - No history of clinically significant interstitial lung disease and/or pulmonary fibrosis - No prior hypersensitivity or unanticipated severe reaction to fluoropyrimidine therapy, fluorouracil, or platinum-based compounds PRIOR CONCURRENT THERAPY: - No prior chemotherapy for metastatic or relapsed disease - More than 4 weeks since prior major surgery and recovered - More than 4 weeks since prior participation in any investigational drug study - At least 6 months since prior adjuvant fluoropyrimidine therapy - No other prior fluoropyrimidines - At least 6 months since prior adjuvant platinum-based therapy - No other prior platinum-based therapy - No concurrent radiotherapy to the head and neck - No other concurrent chemotherapy |
Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (complete response and partial response) | No | ||
Secondary | Toxicity as measured by NCI CTC | Yes | ||
Secondary | Survival | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |